Paeds SAQs · endocrinology-diabetes-and-growth
Obesity: assessment, complications and treatment — formative SAQs
Two formative short-answer questions on childhood obesity classification with adult crossover, systematic comorbidity screening and secondary-cause exclusion, and staged weight-neutral management including pharmacotherapy and surgery.
On this page & tools
Target exams
SAQ 1 — Classification, comorbidity screening and secondary-cause exclusion (10 marks)
A 10-year-old boy is referred because his BMI plots above the 97th percentile for age and sex. He has acanthosis nigricans and his father has type 2 diabetes. The father asks whether his son is "obese and sick," and wants to know what to do. [1] [5]
Questions
- Classify his weight status using the correct BMI-for-age definitions, and state the severe-obesity threshold and the adult crossover. (3 marks) [1] [5]
- Outline the baseline comorbidity investigations you would order and why, naming the four core screens. (4 marks) [1] [2]
- Describe how you would decide whether to investigate for a secondary or syndromic cause, and which red-flag features would trigger testing. (3 marks) [2]
Model answer
Classification (3). Obesity is defined as a BMI at or above the 95th percentile for age and sex on a CDC or WHO growth reference; this boy plots above the 97th percentile, so he meets obesity. Severe obesity is defined as a BMI at least 120 percent of the 95th percentile, or an absolute BMI of at least 35. I would calculate his percentage of the 95th percentile to determine whether he has crossed into severe obesity, because that threshold drives escalation. At 18 years the classification switches to adult cut-offs (overweight at least 25, obesity at least 30). I would use person-first, weight-neutral language with the family rather than the word "obese" directed at the child. [1] [5]
Baseline comorbidity investigations (4). The four core screens are fasting glucose or HbA1c to detect pre-diabetes or type 2 diabetes (warranted by his acanthosis and family history), a fasting lipid panel for dyslipidaemia, ALT to screen for metabolic dysfunction-associated steatotic liver disease, and blood pressure with an appropriately sized cuff. I would add an oral glucose tolerance test if fasting glucose sits in the pre-diabetes range. Given his acanthosis, I am specifically alert to insulin resistance and glucose intolerance. [1] [2]
Secondary-cause work-up (3). Secondary-cause testing is selective, not universal, and is triggered by red-flag features. In a thriving child of normal height with a straightforward family history, a blanket endocrine screen has a low yield. I would investigate if he had short stature relative to the family, decelerating growth, developmental delay, dysmorphism, hyperphagia, Cushingoid features, or a temporal link to a medication. In this boy, the acanthosis and family history point to primary insulin resistance, so I would not order TSH, cortisol or genetic testing unless a red flag emerged. [2]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References8Show ledgerHide ledger
- [1]Hampl SE, Hassink SG, Skinner AC Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics, 2023.PMID 36622115
- [2]Styne DM, Arslanian SA, Connor EL Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. Journal of clinical endocrinology and metabolism, 2017.PMID 28359099
- [4]Simmonds M, Llewellyn A, Owen CG Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obesity reviews, 2016.PMID 26696565
- [5]Kelly AS, Barlow SE, Rao G Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. Circulation, 2013.PMID 24016455
- [6]Inge TH, Laffel LM, Jenkins TM Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. JAMA pediatrics, 2018.PMID 29532078
- [7]Vos MB, Abrams SH, Barlow SE NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children. Journal of pediatric gastroenterology and nutrition, 2017.PMID 28107283
- [12]Kelly AS, Auerbach P, Barrientos-Perez M A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine, 2020.PMID 32233338
- [13]Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine, 2022.PMID 36322838